Randomised, double-blind, placebo-controlled study evaluating the effect of allopurinol on the risk of cardiovascular events in patients with high and very high cardiovascular risk, including the presence of long-COVID-19 syndrome: the ALL-VASCOR study protocol.

Katarzyna LewandowskaDawid LipskiPaweł UruskiKrzysztof NarkiewiczAndrzej JanuszewiczJacek WolfAleksander PrejbiszMarek RajzerAndrzej WięcekAndrzej Tykarski

Published in: BMJ open (2024)

EudraCT: 2022-003573-32, 27 October 2022, ClinicalTrials: NCT05943821, 13 July 2023.

Keyphrases

double blind
cardiovascular events
study protocol
placebo controlled
clinical trial
coronary artery disease
coronavirus disease
randomized controlled trial
sars cov
open label
cardiovascular disease
phase iii
case report
respiratory syndrome coronavirus